实用肝脏病杂志 ›› 2020, Vol. 23 ›› Issue (3): 328-331.doi: 10.3969/j.issn.1672-5069.2020.03.007

• 实验性肝炎 • 上一篇    

柚皮素脂质体对非酒精性脂肪性肝病大鼠脂质代谢的影响及机制研究

唐晓飞,钟梦菊,沈海娟   

  1. 214000 江苏省无锡市第五人民医院药剂科(唐晓飞,钟梦菊);
    苏州医科大学第一附属医院药剂科(沈海娟)
  • 发布日期:2020-05-27
  • 通讯作者: 钟梦菊,E-mail:584780560@qq.com
  • 作者简介:唐晓飞,女,33岁,大学本科,主管药师
  • 基金资助:
    南京医科大学科技发展基金项目(编号:2013NJMU195)

Effect of naringenin Liposomes on lipid metabolism in nonalcoholic fatty liver disease rats

Tang Xiaofei, Zhong Mengju, Shen Haijuan   

  1. Fifth People's Hospital. Wuxi 214000,Jiangsu Province, China
  • Published:2020-05-27

摘要: 目的 研究柚皮素脂质体对高糖高脂饮食诱导的非酒精性脂肪性肝病(NAFLD)大鼠脂质代谢的影响及其机制。方法 将50只SD大鼠随机分为对照组、模型组、柚皮素组、柚皮素脂质体Ⅰ组和柚皮素脂质体Ⅱ组。除对照组大鼠外,其余四组大鼠均采用高糖高脂饲料饲养建立模型,并分别给予生理盐水、柚皮素30 mg·kg-1·d-1、柚皮素脂质体20 mg·kg-1·d-1和柚皮素脂质体30 mg·kg-1·d-1腹腔注射,观察12 w。采用ELISA法检测血清超氧化物歧化酶(SOD)、过氧化氢酶(CAT)和丙二醛(MDA)水平,采用Western blot法检测肝组织Nrf2蛋白表达,采用RT-PCR法检测肝组织Nrf2 mRNA水平。结果 模型组大鼠体质量、肝质量、血清TC、TG、ALT、AST、SOD、CAT和MDA水平分别为(547.6±19.8)g、(12.9±0.3)g、(1.2±0.2)mmol/L、(2.6±0.2)mmol/L、(69.8±5.3)U/L、(229.6±18.2)U/L、(29.9±6.4)U/L、(26.5±2.4)U/mg和(11.7±1.1)nmol/mL,而柚皮素组、柚皮素脂质体Ⅰ组和柚皮素脂质体Ⅱ组大鼠上述大部分指标均有不同程度的下降(P<0.05),仅SOD和CAT水平显著升高(P<0.05);柚皮素组、柚皮素脂质体Ⅰ组和柚皮素脂质体Ⅱ组大鼠肝组织Nrf2蛋白表达和Nrf2 mRNA水平均显著高于模型组。结论 柚皮素脂质体可有效降低NAFLD大鼠血脂水平,促进SOD和CAT生成,其机制可能与激活Nrf2有关。

关键词: 非酒精性脂肪性肝病, 柚皮素, 脂质体, Nrf2基因, 大鼠 ,  ,  

Abstract: Objective The aim of this study was to investigate the effect and possible mechanism involved of naringenin liposome on lipid metabolism in rats with non-alcoholic fatty liver disease (NAFLD) induced by high glucose and fat diet. Methods Fifty male SD rats were randomly divided into control, model, naringenin, naringenin liposome group I and naringenin liposome group II with 10 rats in each. Except the rats in the control, the rats in other four were fed with high-sugar and high-fat diets, receiving intraperitoneal injection of normal salt, 30 mg·kg-1·d-1 naringenin, 20 mg·kg-1·d-1 and 30 mg·kg-1·d-1 of naringenin liposomes, respectively, for 12 weeks. Serum superoxide dismutase (SOD), catalase (CAT) and malonaldehyde (MDA) levels were detected by ELISA, and Nrf2 mRNA and its protein were assayed by RT-PCR and Western blot, respectively. Results The body weight, liver mass, serum TC, TG, ALT, AST, SOD, CAT and MDA levels in the model group were (547.6±19.8) g, (12.9±0.3) g, (1.2±0.2) mmol/L, (2.6±0.2)mmol/L, (69.8±5.3) U/L, (229.6±18.2) U/L, (29.9±6.4) U/L, (26.5±2.4) U/mg and (11.7±1.1) nmol/mL, and they all, but SOD and CAT, decreased in naringin-intervened, naringin liposome group I and naringin liposome group II (P<0.05); Nrf2 protein and Nrf2 mRNA in the liver tissues in naringenin group, naringenin liposome group I and naringenin liposome group II increased as compared to those in the model group. Conclusion Naringenin liposome effectively reduce the blood lipid levels in rats with NAFLD, which might be related to the production of SOD and CAT and activation of Nrf2 gene.

Key words: Nonalcoholic fatty liver diseases, Naringenin, Liposomes, Nrf2 gene, Rats